Loading…
Spyre Therapeutics, Inc. is projected to rise to $133.72 by 2027, a +37% move from its current price of $97.74. SYRE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $94.33 | $97.81 | $101.41 | +0.07% |
| Jul 15 | $92.98 | $97.87 | $103.02 | +0.13% |
| Jul 16 | $91.98 | $97.94 | $104.28 | +0.20% |
| Jul 17 | $91.15 | $98.00 | $105.37 | +0.27% |
| Jul 18 | $90.44 | $98.07 | $106.34 | +0.33% |
| Jul 19 | $89.80 | $98.13 | $107.24 | +0.40% |
| Jul 20 | $89.22 | $98.20 | $108.08 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $89.22 | $98.20 | $108.08 | +0.47% |
| Week 2 | $86.15 | $98.66 | $112.98 | +0.94% |
| Week 3 | $83.96 | $99.12 | $117.02 | +1.41% |
| Week 4 | $82.21 | $99.58 | $120.63 | +1.89% |
| Week 5 | $80.75 | $100.05 | $123.97 | +2.36% |
| Week 6 | $79.48 | $100.52 | $127.12 | +2.84% |
| Week 7 | $78.37 | $100.99 | $130.15 | +3.33% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Spyre Therapeutics, Inc. is a clinical stage biotechnology company focused on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 — anti-TL1A mAbs designed to bind to TL1A.
It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc.
in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Spyre Therapeutics, Inc. (SYRE) is a biotechnology company focused on therapeutics for IBD and rheumatic diseases, including a portfolio of antibody programs such as SPY001, SPY002, SPY072, SPY003 and various combination mAb programs. The name change to Spyre Therapeutics occurred in November 2023, and the company traces its incorporation back to 2013 with headquarters in Waltham, Massachusetts.
As of now, the stock symbol is SYRE, with a current price of $94.23 and a market cap of $8.18B, ranking 1043 in market size. The asset sits in the Healthcare sector and is listed as a biotechnology company focused on clinical-stage therapeutics for IBD and rheumatic diseases.
A major floor 59.2% below — a decisive break under it would weaken the trend.
The nearest floor, 29.2% below — buyers have tended to step in here.
Price is pressing into resistance (2.6% away) — a breakout level to watch.
A major ceiling 23.0% above — clearing it would confirm fresh momentum.
Key SYRE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SYRE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $94.97 | Buy | $95.44 | Buy |
| MA 10 | $91.72 | Buy | $92.93 | Buy |
| MA 20 | $89.69 | Buy | $89.15 | Buy |
| MA 50 | $79.74 | Buy | $80.01 | Buy |
| MA 100 | $64.91 | Buy | $68.05 | Buy |
| MA 200 | $46.22 | Buy | $53.39 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.18 | Neutral |
| Stoch RSI (14) | 44.53 | Neutral |
| CCI (20) | 117.14 | Buy |
| Williams %R (14) | -18.32 | Info |
| MACD (12,26,9) | 0.39 | Buy |
| ROC (12) | 0.71 | Buy |
| Bollinger %B (20,2) | 0.86 | Neutral |
| Stochastic %K (14) | 81.68 | Sell |
| TRIX (15) | 0.83 | Buy |
| Awesome (5,34) | 11.95 | Buy |
| Ultimate (7,14,28) | 71.26 | Sell |
| Momentum (10) | 9.07 | Buy |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 99.08 | Sell |
| ADX (14) | 23.40 | Buy |
| ATR (14) | 2.77 | Info |
The near-term technical picture is bullish overall. RSI14 is 60, suggesting momentum is not overbought but leaning higher. The stock trades above the SMA50 of $78.10 and well above the SMA200 of $44.99, which is typically constructive for trend depth.
Key support is at $69.16 and resistance at $100.32, framing a near-term range that reflects ongoing volatility. The 30-day range spans from $72.88 up to $121.83, indicating substantial movement within the month. Annualized volatility sits at 70%, underscoring that daily swings can be sizable while the mid-range indicators remain constructive.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $29.96 | $97.74 | $147.06 | 0% | Neutral | |
| $103.24 | $133.72 | $185.05 | +37% | Bullish | |
| $134.73 | $181.33 | $262.98 | +86% | Bullish | |
| $159.28 | $221.38 | $332.96 | +127% | Bullish | |
| $177.32 | $253.60 | $393.19 | +159% | Bullish | |
| $184.18 | $270.42 | $430.47 | +177% | Bullish | |
| $182.89 | $275.23 | $448.55 | +182% | Bullish | |
| $209.97 | $323.43 | $538.42 | +231% | Bullish | |
| $256.20 | $403.54 | $684.96 | +313% | Bullish | |
| $304.44 | $489.92 | $846.69 | +401% | Bullish | |
| $369.46 | $656.60 | $1,222.87 | +572% | Bullish | |
| $729.65 | $1,551.18 | $3,216.23 | +14.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $29.96 | $97.74 | $115.31 | +0.00% |
| August 2026 | $83.47 | $99.34 | $122.01 | +1.64% |
| September 2026 | $86.45 | $103.88 | $129.46 | +4.56% |
| October 2026 | $85.54 | $103.62 | $130.74 | -0.24% |
| November 2026 | $87.11 | $106.25 | $135.43 | +2.54% |
| December 2026 | $93.11 | $114.30 | $147.06 | +7.58% |
Click any year to see its month-by-month SYRE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SYRE price prediction for 2026 points to an average of $97.74 (low $29.96, high $147.06) — a potential gain of 0% on today's $97.74. Price action looks broadly range-bound.
In 2027, SYRE is projected to trade between $103.24 and $185.05, averaging $133.72 — a potential gain of +37% from today's $97.74. That is up +37% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Spyre Therapeutics, Inc.'s 2028 outlook centres on $181.33, within a $134.73 to $262.98 range. That is up +36% on the projected 2027 average. That marks a +86% change versus current levels. Momentum favours further upside here.
By 2029, SYRE could reach as high as $332.96, with a base case around $221.38 and support toward $159.28 — roughly +127% from $97.74. Buyers look set to stay in control over this stretch.
Expect SYRE to range from $177.32 to $393.19 through 2030. The $253.60 average target implies a +159% move from current prices. That is up +15% on the projected 2029 average. Momentum favours further upside here.
The SYRE price prediction for 2031 points to an average of $270.42 (low $184.18, high $430.47) — a potential gain of +177% on today's $97.74. Buyers look set to stay in control over this stretch.
In 2032, SYRE is projected to trade between $182.89 and $448.55, averaging $275.23 — a potential gain of +182% from today's $97.74. That is up +2% on the projected 2031 average. Momentum favours further upside here.
Spyre Therapeutics, Inc.'s 2033 outlook centres on $323.43, within a $209.97 to $538.42 range. That is up +18% on the projected 2032 average. That marks a +231% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, SYRE could reach as high as $684.96, with a base case around $403.54 and support toward $256.20 — roughly +313% from $97.74. Momentum favours further upside here.
Expect SYRE to range from $304.44 to $846.69 through 2035. The $489.92 average target implies a +401% move from current prices. That is up +21% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The SYRE price prediction for 2040 points to an average of $656.60 (low $369.46, high $1,222.87) — a potential gain of +572% on today's $97.74. Momentum favours further upside here.
In 2050, SYRE is projected to trade between $729.65 and $3,216.23, averaging $1,551.18 — a potential gain of +14.9x from today's $97.74. That is up +136% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SYRE today (≈ 10.231226 SYRE) could be worth
$15,870.48
+$14,870.48 (+1487%) by 2050 · US Dollar
Based on the average projected SYRE price of $1,551.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SYREwould be worth at today's price.
$1,000 invested in SYRE on Jul 10, 2025 (≈ 62.656641 SYRE) would be worth
$6,124.06
+$5,124.06 (+512.4%) today · 6.12× · US Dollar
Based on a SYRE entry price of $15.96 vs. today's $97.74.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $86.63 | $1,128.25 | +12.8% |
| 1 month ago | $75.08 | $1,301.81 | +30.2% |
| 3 months ago | $51.29 | $1,905.63 | +90.6% |
| 6 months ago | $32.8 | $2,979.88 | +198.0% |
| 1 year ago | $15.96 | $6,124.06 | +512.4% |
| All time (5.0y) ago | $175.25 | $557.72 | -44.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SYRE forecast.
Our base-case forecast reaches $200.00 around 2029.
Implied market cap at $200.00: $17.37B
The multi-year forecast shows a bullish trajectory with rising price expectations beyond 2026. In 2026, the avg price is $94.23 with a min of $29.96 and a max of $145.17, and a neutral sentiment. By 2030, the avg is $247.83 with a max of $391.70 and a bullish stance, reflecting a 163% return potential from the base figures.
In 2040, the avg rises to $640.24 with a max of $1,226.59 and a 579.4% return potential, continuing the bullish sentiment. By 2050, the avg is $1,536.03 with a max of $3,291.21 and a striking 1530.1% return potential, still labeled bullish.
These figures illustrate a wide, upward trajectory across the forecast horizon. They are estimates and not guarantees, and actual outcomes will depend on a variety of factors and market conditions. The forecast indicates growing investor confidence over time, with progressively higher price targets through 2030, 2040, and 2050.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $247.83 with a min of $170.02, a max of $391.70 and a bullish sentiment. The projected ROI is 163%.
The forecast landscape shifts from neutral in 2026 (avg $94.23, ROI 0) to bullish from 2027 onward, with progressively higher avg prices through 2030, 2040, and 2050 and notable ROIs (e.g., 35.7% in 2027, 88.4% in 2028, 132.7% in 2029, up to 1530.1% in 2050). These are estimates, not guarantees.
Yes, the forecast max values show potential above $1,000 by 2040 (max $1,226.59) and beyond, with the 2050 max at $3,291.21. However, 2030 max is $391.70, so crossing $1,000 would occur later in the forecast horizon if assumptions hold.
Current price is $94.23 and market cap is $8.18B.
The 30-day picture is bullish with RSI14 at 60. The SMA50 is $78.10 and the SMA200 is $44.99. Support is at $69.16 and resistance at $100.32, with a 30-day range between $72.88 and $121.83.
Spyre Therapeutics, Inc. Community Discussion
0Share your Spyre Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.